Get Your 7-Day Free Trial! Start Now!
Get Premium to unlock powerful stock data
Manual of Stocks™
United Therapeutics Corp logo

United Therapeutics Corp

$ 228.39 +9.44 (+4.31%) 09:08 PM EST
Warning! GuruFocus has detected 1 Severe warning sign with UTHR. Subscribe to check it out.
P/E:
15.81
P/B:
2.48
Market Cap:
$ 10.35B
Enterprise V:
$ 8.88B
Volume:
827.98K
Avg Vol (2M):
467.61K
Also Trade In:
Volume:
827.98K
Market Cap $:
10.35B
PE Ratio:
15.81
Avg Vol (2-Month):
467.61K
Enterprise Value $:
8.88B
PB Ratio:
2.48
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

United Therapeutics Corp
NAICS : 325412 SIC : 2834
https://www.unither.com
1040 Spring Street, Silver Spring, MD, USA, 20910
Compare
Compare
NYSE:BHVN • NAS:JAZZ • NAS:TECH • NAS:HALO • NAS:BMRN • NAS:LEGN • NAS:SRPT • NAS:EXEL • NAS:ALNY • NAS:IONS • OCSE:NOVO B • ASX:CSL • NAS:REGN • NAS:VRTX • NAS:MRNA • XKRX:207940 • NAS:BNTX • HKSE:02269 • NAS:SGEN • SZSE:300122
Traded in other countries / regions
UTH.Germany • UTHR.USA
Description
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Financial Strength

8/10
Name Current Vs Industry Vs History
Cash-To-Debt 2.84
Equity-to-Asset 0.78
Debt-to-Equity 0.19
Debt-to-EBITDA 0.85
Interest Coverage 48.59
Piotroski F-Score 8/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.83
Distress
Grey
Safe
Beneish M-Score -2.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

7/10
Name Current Vs Industry Vs History
5-Day RSI 93.13
9-Day RSI 86.25
14-Day RSI 79.86
6-1 Month Momentum % -6.96
12-1 Month Momentum % 0.52

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.84
Quick Ratio 8.54
Cash Ratio 7.75
Days Inventory 268.25
Days Sales Outstanding 37.01
Days Payable 11.5

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.1

Financials (Next Earnings Date:2022-08-04 Est.)

UTHR's 30-Y Financials

Guru Trades

See Details
To
EMBED
 SAVE

Insider Trades

See Details
To
EMBED
 SAVE

Gurus Latest Trades with NAS:UTHR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
 SAVE
Performance
Dividend
To
EMBED
 SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

GF Value: $156.91
UTHR
EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1,768.3
EPS (TTM) ($) 14.45
Beta 0.6
Volatility % 36.57
14-Day RSI 79.86
14-Day ATR ($) 8.34862
20-Day SMA ($) 188.4725
12-1 Month Momentum % 0.52
52-Week Range ($) 158.38 - 229.82
Shares Outstanding (Mil) 45.3

Piotroski F-Score Details

Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

United Therapeutics Corp Filings

Document Form Filing Date
No Filing Data

Headlines

See More
Get Premium to unlock powerful stock data
Product
Home
Site Map
Mobile App
Email Alerts
中文
Business
Advertise
Referral Program
Affiliate Program
Information
Career
RSS
FAQ
Contact Us
About
About Us
ADV Part 2A
ADV Part 2B
ADV Part 3
Term of Use
Privacy Policy
Affiliate Program
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.